An efficient LC-QTOF-mass spectrometry method for monitoring naltrexone compliance in urine of opioid-dependent subjects-Reference-Cited by-同舟云学术

An efficient LC-QTOF-mass spectrometry method for monitoring naltrexone compliance in urine of opioid-dependent subjects

Published:2024-02-08 Issue:1 Volume:20 Page:5-9
ISSN:1551-7489
Container-title:Journal of Opioid Management
language:
Short-container-title:J of Opioid Management

Author:

Jain Raka^ORCID,Mandal Piyali,Rana Sachin

Abstract

Naltrexone (NTX) is an orally effective opiate antagonist used in maintenance treatment for opiate dependence. Its utility is limited by the patient's noncompliance. The study aimed to develop an efficient method for the detection of NTX in urine by LC-QTOF-mass spectrometry (MS) and its application to NTX compliance in opioid-dependent subjects. Sample preparation included a dilution step and direct injection to LC-QTOF-MS. Chromatographic separation was achieved with a C-18 column using a mixture of mobile phase 0.1 percent formic acid in water and 0.1 percent formic acid in 95 percent methanol. The calibration curve was linear in the range 1-100 ng/mL with a correlation coefficient higher than 0.996. Precision and accuracy were acceptable, and the recovery efficiency range was 80-85 percent. The current LC-QTOF-MS method is simple, precise, sensitive, and can be used for monitoring NTX compliance among opioid-dependent subjects in a clinical setting.

Publisher

Weston Medical Publishing

Reference16 articles.

1. Johnston LD, O'Malley PM, Miech RA, et al.: Monitoring the Future National Survey Results on Drug Use, 1975-2015: Overview, Key Findings on Adolescent Drug Use. Ann Arbor: Institute for Social Research, the University of Michigan, 2016: 98.

2. Stotts LA, Dodrill CL, Kosten TR: Opioid dependence treatment: Options in pharmacotherapy. Expert Opin Pharmacother. 2009; 10(11): 1727-1740. DOI: 10.1517/14656560903037168.

3. Nunes EV, Rothenberg JL, Sullivan MA, et al.: Behavioral therapy to augment oral naltrexone for opioid dependence: A ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006; 32(6): 503-517.

4. Wall ME, Brine DR, Perez-Reyes M: Metabolism and disposition of naltrexone in man. Drug Metab Dispos. 1981; 9(4): 369-375.

5. Meyer MC, Straughn AB, Lo MW, et al.: Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry. 1984; 45(9 Pt 2): 15-19.